4.7 Article

The potential significance of high avidity immunoglobulin G (IgG) for protective immunity towards SARS-CoV-2

期刊

出版社

ELSEVIER SCI LTD
DOI: 10.1016/j.ijid.2021.01.061

关键词

SARS-CoV-2; Covid-19; Avidity; Protective immunity; Vaccination; Neutralizing antibody

资金

  1. Medical Faculty of the University of Freiburg, Germany

向作者/读者索取更多资源

Avidity plays a crucial role in determining the strength of binding between IgG and its target epitope. The lack of high avidity IgG may lead to insufficient protective immunity. It is suggested to include avidity determination in evaluating vaccination protocols for SARS-CoV-2 to achieve truly protective immunity.
Background: Avidity is defined as the strength of binding between immunoglobulin G (IgG) and its specific target epitope. IgG of high avidity is established during affinity maturation. Failure to achieve high avidity IgG may result in a lack of protective immunity towards infection and disease. It is known that the interaction between SARS-CoV-2 spike protein and its cellular receptor is driven by high affinity. Therefore, it is predictable that protective antibodies towards SARS-CoV-2 should show high affinity/ avidity. Avidity after SARS-CoV-2 infection: Recent findings by several groups demonstrate that the serological response towards infection with SARS-CoV-2 and seasonal coronaviruses is characterized by incomplete avidity maturation, followed by a decline of the serological response. This response might facilitate reinfection, prevent herd immunity and potentially allow repeated cycles of infection. Consequences for vaccination towards SARS-CoV-2: Therefore, the sole focus on antibody titers reached after vaccination towards SARS-CoV-2 might not be sufficient to evaluate the degree of achieved protection. Rather, it is suggested to include avidity determination to optimize vaccination protocols and achieve high avidity IgG directed towards SARS-CoV-2 through vaccination. Avidity determination might also be useful to control for truly protective immunity towards SARS-CoV-2 in individual cases. (c) 2021 The Author(s). Published by Elsevier Ltd on behalf of International Society for Infectious Diseases. This is an open access article under the CC BY license (http://creativecommons.org/licenses/by/4.0/).

作者

我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。

评论

主要评分

4.7
评分不足

次要评分

新颖性
-
重要性
-
科学严谨性
-
评价这篇论文

推荐

暂无数据
暂无数据